IBD Group 2022更新
新闻更新：休斯敦麦戈文医学院beplay苹果手机能用吗的围手术医学中心和麻醉学系的肠道炎症研究
炎症性肠病研究小组：从左，后排：Xiangsheng beplay苹果手机能用吗Huang博士，Agnieszka Czopik博士，Frank Chen，Holger Eltzschig博士。前排：维多利亚·莫塔（Victoria Mota），尤伊（Xiaoyi Yuan）博士，珍妮弗·贝利（Jenifer Baily）博士，扬努·王（Yanyu Wang）博士。
We would like to express our deep gratitude for the continuing generosity of Mr. Brad McWilliams who has supported our efforts to pursue translational studies to identify new treatment approaches for patients suffering from intestinal inflammation and inflammatory bowel disease (IBD). With the help and support of Brad, we were able to move forward with identifying novel therapeutic targets for IBD that could be game changing for IBD patients. We anticipate that our studies lay the groundwork for clinical trials on hypoxia signaling and miRNAs to prevent or treat excessive intestinal inflammation. These targets would be more specific and most likely have less unwanted side effects as compared to the use of steroids.
Over the past 2 years we have further enhanced and grown our IBD research team to explore novel avenues for therapeutic interventions. Specifically, we found important roles for hypoxia-inducible miRNAs as novel IBD treatment targets. These molecules are powerful regulators in a wide variety of diseases and their roles in IBD has only recently gained appreciation. The small size and portability of miRNAs make them attractive candidates for therapeutic interventions in clinical settings. We envision that miRNA therapies have the potential to become a major class of new drugs to treat bowel inflammation in the coming years.
2021 was a highly successful year filled with new discoveries and research directions. As we begin 2022, we have several exciting updates to share:
Our IBD group has grown.
We recently added the talented and experienced IBD researcher,Xiangsheng Huang博士，who joined our team in January 2022. Dr. Huang received his PhD in Biology at the University of Tübingen, Germany. Afterwards, he pursued his postdoctoral training at UTMB and Baylor College of Medicine where he investigated intestinal immune responses to gut microbiota and metabolites in the pathogenesis of IBD. Prior to joining UTHealth, Dr. Huang was an Assistant Researcher at UC Berkeley, where he identified a distinctive role for nuclear receptors in immune regulation of IBD. Through this work, he establishedin vitro免疫细胞分化技术和IBD的独特鼠模型。此外，黄博士在嘌呤能系统在调节肠道免疫反应中的作用方面具有广泛的专业知识，并一直在研究对共生细菌和肠道代谢物反应的免疫细胞。beplay苹果手机能用吗他的经验以及Eltzschig Lab在缺氧驱动的途径方面的专业知识，将使他能够建立新型的生物学范式，这可能会导致未来对人类炎症性肠病的治疗。
IBD研beplay苹果手机能用吗究人员
维多利亚·莫塔（Victoria Mota），研beplay苹果手机能用吗究助理，于2021年夏天加入了我们的IBD研究小组。维多利亚于2021年获得了休斯顿浸信会大学的生物学学士学位。用于研究结肠炎。维多利亚渴望扩大自己的知识并提高她在分子生物学，免疫学和组织学方面的技术专业知识，因为她有助于进行日常实验工作。她最终计划申请分子生物学和免疫学的研究生计划，并希望将来成为一名独立研究人员。beplay苹果手机能用吗我们很高兴能将她加入我们的小组，并感谢她的热情，辛勤工作和朝着卓越的研究迈进。beplay苹果手机能用吗
Research Updated from our IBD Program:
Immediate:我们建立了小鼠结肠炎模型,发展new mutant mouse strains, and designed assays to evaluate the role of the hypoxia/adenosine pathway and microRNAs as regulators of intestinal homeostasis, immune responses, and therapeutic agents in IBD. Our manuscript detailing the role of miR-29, a hypoxia-regulated microRNA, in the development of inflammatory bowel disease and its potential as a therapeutic agent in the clinic is nearing completion. We hope to see this work published in the coming months. The next goal in our studies of miR-29 is to investigate whether this molecule can have a protective effect in the development of colon cancer—a complication which frequently can affect patients who are suffering from IBD over extended time periods.
我们还开始研究称为miR-147的第二个缺氧诱导的microRNA。该分子在不同细胞类型中具有潜在的抗炎活性。我们正在研究miR-147如何调节肠衬肠壁的功能和层下层的淋巴细胞的功能。我们在小鼠模型中的初步数据表明，miR-147对于维持结肠炎期间肠道的完整性至关重要。我们还发现，它可以抑制慢性结肠炎模型中的过度活跃淋巴细胞。我们的下一个目标是验证我们在人类IBD样品中的发现，并研究miR-147作用背后的机制。
未来发展方向：
Brad McWilliams的新支持与最近获得的研究补助金，使我们的小组能够继续增长和积累研究数据。beplay苹果手机能用吗根据过去一年中生成的新型miR-147数据，我们计划提交有竞争力的NIH R01赠款应用程序，以确保对基于microRNA的炎症性肠道疾病和肠道癌症的潜力进行调查的额外资源。IBD组产生了几种新型的鼠标模型，并进行了基因表达筛选，这些筛选将成为我们研究工作和授予写作工作的基石。beplay苹果手机能用吗我们感谢McWilliams先生的持续支持，并期待今年分享更多的研究重点。beplay苹果手机能用吗
将我们的发现从长凳转换为床边：广泛的证据正在进行临床试验的with anti-cancer micro RNAs strongly indicates that therapeutic delivery of specific microRNAs may become a robust strategy for IBD therapy as well. Specifically, with optimization of miRNA delivery systems and improvements in the stability of miRNAs the miR-29-mimic, and possibly the miR-147-mimic may soon become a target of a clinical trial aimed to rein in the overactive lymphocytes that promote intestinal inflammation. There are also already-approved therapeutics that activate HIF and induce hypoxia-dependent microRNAs that will be subject of upcoming clinical efforts for successful translation of such therapeutics from bench to bedside. Our pre-clinical data makes a compelling argument for the use of HIF-stabilizing drugs to alleviate suffering of the IBD patients. We will actively pursue in clinical proof-of-principle studies to translate our findings from bench to bedside, and will soon be moving our basic research findings towards clinical trials in patients suffering from excessive inflammation.
We want to close by again thanking Brad McWilliams for the extremely generous support of our IBD research, and his guidance by emphasizing our efforts on bringing the laboratory research findings towards treatments of patients who are suffering from this incredibly devastating disease.